Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Advertisement
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Sanofi And NIH To Test 3-In-1 Antibody In HIV After Monkey Trial Success

Sanofi's focus on developing multi-specific therapies is being turned to HIV.

Clinical Trials Companies

Refocused Novo Nordisk Says On 'Road To Recovery' After Traumatic 2016

Novo Nordisk's head of international operations says the company has learned from the past, taken corrective steps, and is now on the road to recovery.

Business Strategies Leadership

UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut

UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only through the UK's revamped Cancer Drugs Fund, and at a discounted price.

Commercial Companies

Clustering Of Diabetes Subgroups May Aid Outcome Predicting

This year's EASD meeting in Lisbon heard calls to re-categorize type 2 diabetes into novel subsets, as data suggest the approach could lead to better targeted treatments.

Companies Innovation

Diabetes-CV Disease Link Boosts EASD Buzz

Linkage between cardiovascular disease and type 2 diabetes was a top theme of discussion and data presented at this year's EASD meeting in Portugal's capital.

Metabolic Disorders Cardiovascular

Novo Nordisk Eagerly Prepares To Launch Victoza Nationally In China

Novo Nordisk's diabetes blockbuster Victoza has finally been approved for national roll-out in China and will thus get a fresh launch there in early January.

Business Strategies Commercial
See All
Advertisement
UsernamePublicRestriction

Register